Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22

作者：

Gay, Francesca ^{[1
]}

Cerrato, Chiara ^{[1
]}

Scalabrini, Delia Rota ^{[1
]}

Galli, Monica ^{[1
]}

Belotti, Angelo ^{[1
]}

Zamagni, Elena ^{[1
]}

Ledda, Antonio ^{[1
]}

Grasso, Mariella ^{[1
]}

Angelucci, Emanuele ^{[1
]}

Liberati, Anna Marina ^{[1
]}

Tosi, Patrizia ^{[1
]}

Pisani, Francesco ^{[1
]}

Spada, Stefano ^{[1
]}

Annibali, Ombretta ^{[1
]}

Baraldi, Anna ^{[1
]}

Omede, Paola ^{[1
]}

Galieni, Piero ^{[1
]}

Rizzi, Rita ^{[1
]}

Pescosta, Norbert ^{[1
]}

Ronconi, Sonia ^{[1
]}

Vincelli, Donatella ^{[1
]}

Cafro, Anna Maria ^{[1
]}

Offidani, Massimo ^{[1
]}

Palumbo, Antonio ^{[2
,3
]}

Musto, Pellegrino ^{[1
]}

Cavo, Michele ^{[1
]}

Boccadoro, Mario ^{[1
]}

机构：

[1] European Myeloma Network, GIMEMA, Milan, Italy

[2] Univ Torino, Turin, Italy

[3] Takeda Pharmaceut Co, Zurich, Switzerland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页数：4

共 50 条

[21] A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard- Risk Patients [J].

Gay, Francesca Maria ;

Scalabrini, Delia Rota ;

Belotti, Angelo ;

Galli, Monica ;

Zamagni, Elena ;

Offidani, Massimo ;

Oliva, Stefania ;

Montefusco, Vittorio ;

Zambello, Renato ;

Ledda, Antonio ;

Grasso, Mariella ;

Aquino, Sara ;

Esma, Fabrizio ;

Tosi, Patrizia ;

Pisani, Francesco ;

Annibali, Ombretta ;

Liberati, Anna Marina ;

Baraldi, Anna ;

Galieni, Piero ;

Specchia, Giorgina ;

Pescosta, Norbert ;

Mancuso, Katia ;

Paris, Laura ;

Ribolla, Rossella ;

Coha, Valentina ;

Palumbo, Antonio ;

Musto, Pellegrino ;

Cavo, Michele ;

Boccadoro, Mario .

BLOOD, 2017, 130

[22] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) [J].

Zimmerman, Todd ;

Raje, Noopur S. ;

Vij, Ravi ;

Reece, Donna ;

Berdeja, Jesus G. ;

Stephens, Leonor A. ;

McDonnell, Kathryn ;

Rosenbaum, Cara A. ;

Jasielec, Jagoda ;

Richardson, Paul G. ;

Gurbuxani, Sandeep ;

Nam, Jennifer ;

Severson, Erica ;

Wolfe, Brittany D. ;

Rosebeck, Shaun ;

Stefka, Andrew ;

Dytfeld, Dominik ;

Griffith, Kent ;

Jakubowiak, Andrzej .

BLOOD, 2016, 128 (22)

[23] Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies [J].

Landgren, Ola ;

Attal, Michel ;

Kazandjian, Dickran ;

Roussel, Murielle ;

Jasielec, Jagoda K. ;

Dytfeld, Dominik ;

Anderson, Aparna ;

Kervin, Tara ;

Iskander, Karim ;

Mezzi, Khalid ;

Welliver, Tim ;

Yusuf, Akeem ;

Jakubowiak, Andrzej .

BLOOD, 2019, 134

[24] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) [J].

Zimmerman, T. M. ;

Griffith, K. ;

Jasielec, J. K. ;

Rosenbaum, C. A. ;

McDonnell, K. ;

Marin, J. ;

Bakker, J. ;

Berdeja, J. G. ;

Vij, R. ;

Jakubowiak, A. J. .

HAEMATOLOGICA, 2014, 99 :103-103

[25] VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis [J].

Piedra, Katrina M. ;

Hassoun, Hani ;

Buie, Larry W. ;

Devlin, Sean M. ;

Flynn, Jessica ;

Hultcrantz, Malin ;

Lesokhin, Alexander M. ;

Lu, Sydney X. ;

Mailankody, Sham ;

Shah, Urvi A. ;

Smith, Eric L. ;

Landgren, Ola ;

Korde, Neha ;

Peterson, Tim J. .

BLOOD, 2019, 134

[26] A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group [J].

Gregersen, Henrik ;

Peceliunas, Valdas ;

Remes, Kari ;

Schjesvold, Fredrik H. ;

Abildgaard, Niels ;

Nahi, Hareth ;

Andersen, Niels Frost ;

Vangsted, Annette Juul ;

Klausen, Tobias Wirenfeldt ;

Helleberg, Carsten ;

Carlson, Kristina ;

Frolund, Ulf Christian ;

Axelsson, Per ;

Stromberg, Olga ;

Blimark, Cecilie Hveding ;

Linder, Olle ;

Tsykunova, Galina ;

Waage, Anders ;

Hansson, Markus ;

Gulbrandsen, Nina .

BLOOD, 2019, 134

[27] Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis [J].

Wang, Yuqi ;

Huan, Chen ;

Hanzhen, Zhang ;

Zhang, Shanshan ;

Yuan, Youhai ;

Feng, Ru ;

Wei, Yongqiang ;

Wei, Xiaolei .

BLOOD, 2024, 144 :7031-7031

[28] Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma [J].

Gavriatopoulou, Maria ;

Terpos, Evangelos ;

Ntanasis-Stathopoulos, Ioannis ;

Malandrakis, Panagiotis ;

Eleutherakis-Papaiakovou, Evangelos ;

Papatheodorou, Athanasios ;

Kanellias, Nikolaos ;

Migkou, Magdalini ;

Fotiou, Despina ;

Dialoupi, Ioanna ;

Roussou, Maria ;

Kokkali, Nikoletta-Aikaterini ;

Kastritis, Eftathios ;

Dimopoulos, Meletios A. .

BLOOD, 2019, 134

[29] Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma [J].

Maria Gavriatopoulou ;

Evangelos Terpos ;

Ioannis Ntanasis-Stathopoulos ;

Panagiotis Malandrakis ;

Evangelos Eleutherakis-Papaiakovou ;

Athanasios Papatheodorou ;

Nikolaos Kanellias ;

Magdalini Migkou ;

Despina Fotiou ;

Ioanna Dialoupi ;

Maria Roussou ;

Nikoletta-Aikaterini Kokkali ;

Efstathios Kastritis ;

Meletios A. Dimopoulos .

Blood Cancer Journal, 10

[30] Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma [J].

Gavriatopoulou, Maria ;

Terpos, Evangelos ;

Ntanasis-Stathopoulos, Ioannis ;

Malandrakis, Panagiotis ;

Eleutherakis-Papaiakovou, Evangelos ;

Papatheodorou, Athanasios ;

Kanellias, Nikolaos ;

Migkou, Magdalini ;

Fotiou, Despina ;

Dialoupi, Ioanna ;

Roussou, Maria ;

Kokkali, Nikoletta-Aikaterini ;

Kastritis, Efstathios ;

Dimopoulos, Meletios A. .

BLOOD CANCER JOURNAL, 2020, 10 (03)

← 1 2 3 4 5 →